MedImmune

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

Retrieved on: 
Thursday, April 4, 2024
Biotechnology, AstraZeneca, Merck, Cancer, Doctor of Philosophy, Spacecraft, B7-H4, Antibody, Johnson & Johnson, Immunotoxin, CSO, MedImmune

BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board.

Key Points: 
  • BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board.
  • As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4.
  • “We are delighted to have Dr. Dixit join our Scientific Advisory Board, where he will leverage his exceptional experience in developing antibody-drug conjugates,” said Solomon Langermann, PhD, NextCure’s chief scientific officer.
  • “Rakesh is a world authority on ADCs and has an incredible record of researching and developing them.

Bioforum Expands Leadership Team with Appointment of Michael Goedde as President

Retrieved on: 
Tuesday, March 19, 2024
Automation, ChromeOS, Sanofi, Development, MedImmune, NESS, ICON PLC, Database, CLZ, Goedde, Trustee, CNS, ICON, Biostatistics, Research, Hoechst AG, Society, SDTM, BioGRID, Human Genome Sciences, Parexel, Nursing

NESS ZIONA, Israel, March 19, 2024 /PRNewswire/ -- Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to the global clinical trials industry, today announced the appointment of Michael Goedde as its President. A clinical data management expert whose career in the life sciences industry spans over three decades, Goedde will drive the development and execution of Bioforum's global growth and innovation strategy. 

Key Points: 
  • A clinical data management expert whose career in the life sciences industry spans over three decades, Goedde will drive the development and execution of Bioforum's global growth and innovation strategy.
  • "As we expand our presence in North America and around the world, I'm delighted to welcome Michael to the Bioforum family and confident that his leadership will be invaluable in driving our long-term growth and success."
  • Prior to ICON, Goedde spent four years at Parexel in roles of increasing responsibility, most recently as Vice President of Global Data Operations.
  • He holds a bachelor's degree in computer science from Computer Lern Zentrum (CLZ) Hoechst AG in Frankfurt, Germany.

Proniras Corporation Secures New Series B Financing and Names New Board Members to Support Phase 1 Study of Novel Treatment for Opiate Withdrawal

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, ARCH Venture Partners, Senior, Corporation, GSK plc, MedImmune, Takeda Pharmaceutical Company, Knowledge, Eli Lilly and Company, Opioid, WRF, VBI Vaccines, AstraZeneca, Acquisition, Development, Epilepsy, Public, Growth, General counsel, Vilya, Corporate development, Patient, Venture round, LP, Research, Trial of the century, ARCH, Therapy, DSM-IV codes, Series

PRN-001-01 (tezampanel) is a novel small molecule compound that will be the first parenteral therapeutic to be evaluated for the treatment of symptoms associated with opiate withdrawal in a Phase 1 clinical study.

Key Points: 
  • PRN-001-01 (tezampanel) is a novel small molecule compound that will be the first parenteral therapeutic to be evaluated for the treatment of symptoms associated with opiate withdrawal in a Phase 1 clinical study.
  • In conjunction with the Series B financing, Proniras has appointed Steven Gillis, Ph.D., as Chairman and Atul Saran as an independent member to the Company’s Board of Directors.
  • "Their wealth of knowledge and industry experience will be instrumental in guiding Proniras through its next phase of growth.
  • We look forward to their leadership and contributions as we continue to advance Proniras through the next stages of product development."

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer

Retrieved on: 
Monday, January 8, 2024
AMAG Pharmaceuticals, Vaccine, Hospital, Immunoglobulin A, Nephrology, Amgen, Biotechnology, AstraZeneca, Drug development, Allergy, IgA nephropathy, MAA, MedImmune, Darbepoetin alfa, Johns Hopkins University, NDA, Medical microbiology, California State University, Therapy, GSK, Stanford University Medical Center, Peanut allergy, Regulatory affairs, Kidney, SVP, Patient, Hematology, Iron(II,III) oxide, Pharmaceutical industry

The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.

Key Points: 
  • The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.
  • ; and William D. Turner as Chief Development Officer, effective immediately.
  • Rob and Bill each have successfully guided multiple therapies through late clinical development, regulatory approval and commercial launch.
  • This is a key moment for Vera as we continue to advance the strategy for our late-stage clinical program,” said Marshall Fordyce, M.D., Chief Executive Officer of Vera Therapeutics.

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Retrieved on: 
Monday, November 27, 2023
Opus, Grifols, Marketing, Old Dominion University, Information technology, BBA, Retina, Diabetic retinopathy, MedImmune, MBA, James Madison University, GSK, Ophthalmology, CNS, OCUP, HIV, Merck, Pharmaceutical industry

“Joe is a highly accomplished pharmaceutical executive, and we are thrilled to welcome him to Ocuphire as Chief Operating Officer,” said Dr. George Magrath, CEO of Ocuphire.

Key Points: 
  • “Joe is a highly accomplished pharmaceutical executive, and we are thrilled to welcome him to Ocuphire as Chief Operating Officer,” said Dr. George Magrath, CEO of Ocuphire.
  • Joe brings diverse experience, including in ophthalmology, from some of the world’s leading life science companies.
  • From 2014 to 2017, he served as Chief Operating Officer at Parion Sciences.
  • Mr. Schachle received an MBA from Old Dominion University, VA, and a BBA in Marketing from James Madison University, VA.

enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors

Retrieved on: 
Tuesday, December 19, 2023
Orexigen Therapeutics, Inovio Pharmaceuticals, CPA, Audit committee, Ernst & Young, MedImmune, Therapy, Controller, BCG, Chairperson, PSINet, Patient, Circassia Group, Compensation, Spark Therapeutics, History, Senior, Management

Ms. Zoth is an experienced Board of Directors member, having served in various roles at other companies, including Board Chair, Lead Independent Director, and Audit Committee Chair, as well as on Compensation, Transaction, Finance and Special Strategic Committees.

Key Points: 
  • Ms. Zoth is an experienced Board of Directors member, having served in various roles at other companies, including Board Chair, Lead Independent Director, and Audit Committee Chair, as well as on Compensation, Transaction, Finance and Special Strategic Committees.
  • She is currently serving on the Boards of the publicly traded companies Lumos Pharma, Inovio Pharmaceuticals, and 89 Bio.
  • Her past Board experience includes Zymeworks, Spark Therapeutics, Aeras, Orexigen Therapeutics, Circassia Pharmaceuticals, Hyperion Therapeutics, and Ikaria.
  • "I am honored to join the Board of Directors and to serve as Audit Committee Chair to help build a successful future for enGene and patients in need."

Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors

Retrieved on: 
Wednesday, November 15, 2023
Aston, Engineering physics, NYSE, NMT, Francis Crick Institute, AstraZeneca, Spacecraft, Therapy, Biology, ADC, CSO, Patient, Sofinnova, MedImmune, Chemical engineering, Chris, Aston University, MBA, Drug discovery, University, Cancer, Imperial College London, IMD, Institution of Chemical Engineers, Knowledge, New York Stock Exchange, Fine chemical, Pharmaceutical industry

Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space.

Key Points: 
  • Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space.
  • Dr Martin was instrumental in co-founding ADC Therapeutics (NYSE: ADCT) in Jan 2012 and served as its CEO since inception until May 2022.
  • Alongside his role as Chairman of Myricx, he is also Chairman of the Board of Tokamak Energy Ltd, and Tagworks Pharmaceuticals BV, and a Director on the Board of Osivax SAS.
  • Dr Robin Carr, Myricx CEO and Board Director, said, “We are thrilled that Chris has joined our Board and taken on the role of Chairman.

Aiolos Bio Strengthens and Expands Leadership Team with Key Appointments

Retrieved on: 
Tuesday, December 12, 2023
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, COPD, Atlas Venture, Entrepreneurship, DBV Technologies, Rockefeller University, Investment, PD, Respiratory system, Patient, Strategic planning, Element, Doctor of Philosophy, M&A, Galvani Bioelectronics, GSK, MedImmune, Caregiver, Atopic dermatitis, R, Publishing, Atlas, McKinsey & Company, Asthma, Pharmaceutical industry, Neuroscience, Aeolus, Genentech

“We are delighted to welcome René and Tapan as key members of our leadership team at this exciting time for the Company as we prepare to initiate a Phase 2 clinical trial for our lead drug candidate, AIO-001, in moderate-to-severe asthma patients,” said Khurem Farooq, Co-Founder and Chief Executive Officer of Aiolos Bio.

Key Points: 
  • “We are delighted to welcome René and Tapan as key members of our leadership team at this exciting time for the Company as we prepare to initiate a Phase 2 clinical trial for our lead drug candidate, AIO-001, in moderate-to-severe asthma patients,” said Khurem Farooq, Co-Founder and Chief Executive Officer of Aiolos Bio.
  • “I’m thrilled to be joining the talented team at Aiolos Bio,” said Dr. Van der Merwe.
  • We look forward to presenting and publishing data in 2024.” Dr. Van der Merwe will join Aiolos Bio effective January 2,2024.
  • He joins Aiolos Bio from Bain Capital Life Sciences where he led and managed investments across therapeutic areas.

Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer

Retrieved on: 
Friday, December 1, 2023
MedImmune, Skin, Research and development, Organization, Food, Public key certificate, RNA interference, Physician, Royal college, Squamous-cell carcinoma, Molecular biology, McGill University, Internal medicine, Therapy, University, Harvard Medical School, Development, Drug development, Pharmaceutical industry, Chiron

and Suzhou, China, Dec. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced the promotion of Dr. Francois Lebel, M.D., to Chief Medical Officer.

Key Points: 
  • and Suzhou, China, Dec. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced the promotion of Dr. Francois Lebel, M.D., to Chief Medical Officer.
  • Dr. Lebel enters this new role after serving as Senior Vice President for preclinical and clinical development since July 2023.
  • "I am honored to lead Sirnaomics' RNAi pipeline through clinical development, building upon my experiences with the Company, and with outside investigators and international regulatory bodies, I hope my experiences of successfully achieving eight product marketing approvals will bring Sirnaomics to the commercial stage," said Dr. Lebel, M.D., Chief Medical Officer of Sirnaomics.
  • His most recent senior leadership roles include Executive Vice President for Research & Development and Chief Medical Officer Spectrum, where he was responsible for Preclinical and Clinical Development, Regulatory Affairs and Pharmacovigilance/Drug Safety.

Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities

Retrieved on: 
Friday, November 17, 2023
ID, Corporation, Business development, Chemistry, NVAX, AstraZeneca, Senior, Commercial Operating System, Novavax, Boston Scientific, Suffolk University Law School, Hologic, Vaccine, Vancouver Island University, Rationalization, MedImmune, COVID-19, Long Island University, Business administration, Mallinckrodt, Dell, R, CMC, Infection, Syracuse University, Business, Master of Business Administration, Management, Science, New York University

GAITHERSBURG, Md., Nov. 17, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced changes to its executive leadership team designed to enhance focus on its strategic priorities and continue the evolution of the Company's scale and structure announced last week.

Key Points: 
  • GAITHERSBURG, Md., Nov. 17, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced changes to its executive leadership team designed to enhance focus on its strategic priorities and continue the evolution of the Company's scale and structure announced last week.
  • In this role, Mr. Trizzino will lead the commercial; chemistry, manufacturing and controls or CMC; and regulatory functions.
  • He will continue to serve on the Company's executive leadership team.
  • Mr. Casey will also serve on the Company's executive leadership team.